Seanglong Te, M.D.
Collaborative Neuroscience Research, LLC
Collaborative Neuroscience Network, LLC
19401 S. Vermont Avenue, Suite F-100
Torrance, CA 90502

CONTACT INFORMATION:

Site Selection and Information:
Bobbie Theodore, Alliance Director
Tel. (916) 939-6696
Fax (208) 575-3169
Email: clinicaltrials@alliancesites.com

AFFILIATIONS:

Collaborative Neuroscience Research, LLC
Collaborative Neuroscience Network, LLC
12772 Valley View Street, Suite 3
Garden Grove, CA 92845

Collaborative Neuroscience Research, LLC
Collaborative Neuroscience Network, LLC
2600 Redondo Avenue, Suites 415 & 500
Long Beach, CA 90806

Ocean View Psychiatric Health Facility
2600 Redondo Avenue, Suite 500
Long Beach, CA 90806

EDUCATION:

2003, Doctor of Medicine
Ross University School of Medicine, Portsmouth, Dominica

1997: BS in Biological Science
University of California – Irvine, Irvine, CA

RESIDENCIES:

Chief Resident
Warren Hospital Family Medicine Residency Program, Phillipsburg, NJ
Residency 2006 -2009

CERTIFICATION:

Licensed in California, December 2008
Diplomate American Board of Family Medicine

LICENSURE:

Licensed Physician and Surgeon, State of California, License No. A106386

PROFESSIONAL EXPERIENCE:

Investigator, 2017- Present
Collaborative Neuroscience Research, LLC, Long Beach, CA
Collaborative Neuroscience Network, LLC, Long Beach, CA

Sub-Investigator, 2011- Present
Collaborative Neuroscience Research, LLC, Long Beach, CA
Collaborative Neuroscience Network, LLC, Long Beach, CA

Urgent Care/Family Medicine, 2012 – Present
Memorial Prompt Care, Huntington Beach, CA

Urgent Care, 2010- Present
Healthcare Partner Medical, Long Beach, CA.

Urgent Care, 2009 – 2012
Magan Medical Clinic, Covina, CA
Supervise PA's and treat common ailments, including Run Codes, laceration repairs, I & D abscesses, chest pain, Sport injuries, splinting, Asthma/COPD exacerbations.

CERTIFICATIONS:

BLS, ACLS

RESEARCH:

Accuracy of albumin adjusted calcium versus ionized serum calcium in ICU patients. Presented at Warren Hospital for Research Symposium.

Research Coordinator, 2003-2006
VA Medical Center, Long Beach, CA
Investigation into Hemochromatosis – Prevalence among VA patients and possible alternative guidelines for screening.

CLINICAL TRIAL EXPERIENCE:

Phase I • Asthma • Bipolar Disorder • Chronic Pain • Constipation • Crohn's Disease
Depression • Diabetes • Ethno-Bridging • Healthy • Hypercholesterolemia
Iron Deficiency Anemia • Irritable Bowel Syndrome • Men's and Women's Health
Opioid Induced Constipation • Osteoarthritis • Painful Lumbar Radiculopathy
Schizophrenia and Schizoaffective Disorders

SUB-INVESTIGATOR TRIAL EXPERIENCE:

Phase I Depression

A Phase I, Two-Part, Double-Blind, Placebo-Controlled, Twice Daily Dose Study of XXX in Adult Participants with Major Depressive Disorder (Part B)

A Phase I, Two-Part, Double-blind, Placebo-controlled, Single- and Multiple-Dose Study of XXX in Adult Participants with Major Depressive Disorder (Part A)

Phase I Ethno-Bridging

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of XXX in Healthy Japanese and Non-Japanese Participants

Phase I Healthy

A Phase 0, Multi-Center Study in Schizophrenic Patients and Healthy Volunteers to Validate XXX Biomarkers for Use in Therapeutic Trials

A Phase I, Relative Bioavailability Study of an Extended Release (ER)Tablet Formulation of XXX Compared to an Intermediate Release (IR) Capsule Formulation in Healthy Volunteers

A 2-Part, Phase I, Study of XXX Pharmacodynamics and Pharmacokinetics Alone and in the Presence of XXX or XXX

A Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of XXX in Healthy Volunteers

A Phase I, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of XXX in Healthy Volunteers

Phase I Schizophrenia and Schizoaffective Disorders

A Phase Ib Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of XXX in Subjects with Schizophrenia

SUB-INVESTIGATOR TRIAL EXPERIENCE (*continued*):

A Phase IV, Open-label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of 180 mg XXX Subcutaneous Injection Following a Switch From 6 mg Oral XXX in Patients With Clinically Stable Schizophrenia

A Phase I, Randomized, Double-blind, Placebo-controlled, Ascending Dose study to Determine Efficacy, Pharmacokinetic and Safety of XXX in Agitation associated with Schizophrenia or Schizoaffective Disorder

A Phase Ib, Open-label, Multiple-dose, Randomized, Parallel-arm, Safety, Tolerability, and Pharmacokinetic Trial of XXX Intramuscular Depot Administered in the Gluteal Muscle in Adult Subjects With Schizophrenia or Bipolar I Disorder

An Open-label, Single- and Multiple-dose, Pharmacokinetic, Safety, and Tolerability Trial of XXX Administered in the Deltoid or Gluteal Muscle in Adult Subjects with Schizophrenia or Bipolar I Disorder

A Phase I, Open Label, Parallel-Design, Single Dose Study to Assess the Relative Bioavailability of XXX Extended-Release Suspension for Subcutaneous Administration XXX, in Vials compared to Prefilled Syringes, in Patients with Schizophrenia or Schizoaffective Disorder

Bipolar Disorder

A Phase IIIb Double-blind, Placebo-controlled, Randomized, Withdrawal Multicenter Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of XXX in a Dose Reduction Paradigm in the Prevention of Relapse in Bipolar I Disorder Patients Whose Current or Most Recent Episode is Manic, with or without Mixed Features

A Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of XXX in the Treatment of Subjects with Bipolar I Disorder

A Multicenter, Randomized, Double-blind Trial of XXX versus Placebo for the Acute Treatment of Subjects Manic Episodes, With or Without Mixed Features, Associated With Bipolar I Disorder

A Long-Term Open-Label Study of the Safety and Tolerability of XXX in Patients with Bipolar I Disorder

A Randomized, 6-Week, Double-blind, Placebo-controlled, Flexible-dose, Parallel-group study of XXX or XXX for the treatment of Bipolar Depression

A 24-Week, Flexible-Dose, Open-Label Extension Study of XXX for the Treatment of Bipolar I Depression

SUB-INVESTIGATOR TRIAL EXPERIENCE (*continued*):

A 6-Month, Open-Label, Flexible-Dosage (150-200 mg/day) Extension Study of the Safety and Efficacy of XXX Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

A Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of XXX Treatment (150 and 200 mg/day) as Adjunctive Therapy in Adults with Major Depression Associated with Bipolar I Disorder

Depression

A Phase IIb, Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study to Evaluate the Efficacy and Safety of 2 Fixed Doses (5.0 mg or 2.5 mg) of XXX in Adult Patients with Major Depressive Disorder

A Phase II, Open-label, 8-Week Study of Safety and Efficacy for Adjunctive XXX Treatment in Adults With Parkinson's Disease and Inadequately Controlled Depression

A Phase IIIb, 12-Week, Double-Blind, Placebo-Controlled, Multi-center Study Evaluating the Safety and Efficacy of XXX1MG Bid for Smoking Cessation in Subjects with Depression

A Phase IIa, Double Blind, Placebo-Controlled Study of the Efficacy and Safety of XXX Augmentation of Antidepressant Therapy in Major Depression

A Double-Blind, Randomized, Multi-center, Placebo-Controlled, Relapse Prevention Study with XXX in Out-Patient Adults with Major Depressive Disorder

A Phase III, Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral XXX Combination Therapy in Patients With Major Depressive Disorder

A Multi-center, Randomized, Double-Blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral XXX Combination Therapy in Patients with Major Depressive Disorder

A Multi-center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Phase III, Efficacy and Safety Study of 3 Fixed Dose Groups of XXX as an Adjunct to an Antidepressant in Patients with Major Depressive Disorder Who Exhibit an Inadequate Response to Antidepressant Therapy

A Multi-center, Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Phase III, Long-Term Safety and Tolerability Study of XXX as an Adjunct to an Antidepressant in Patients with Major Depressive Disorder Who Exhibit an Inadequate response to Antidepressant Therapy

A 52-week, Multi-center, Open-label, Study of the Safety and Tolerability of XXX in patients with Major Depressive Disorder (MDD)

SUB-INVESTIGATOR TRIAL EXPERIENCE (*continued*):

Diabetes

A Phase III, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Effects of XXX vs. XXX in Subjects with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control by Metformin

A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Add-on Study of XXX in Adults with Uncontrolled Type 2 Diabetes on Metformin Therapy

A Phase II, A Randomized, Double-blind, Parallel Group, Multicenter, Placebo-controlled, Dose-ranging Study to Evaluate the Glycemic Effects, Safety, and Tolerability of XXX Delayed-Release in Subjects with Type 2 Diabetes Mellitus

A Multiple dose trial examining dose range, escalation and efficacy of oral XXX in subjects with Type 2 Diabetes

A Phase III, Randomized, Active Comparator, Double-Blind, Multi-Center Study to Compare the Efficacy, Safety and Tolerability of XXX as Add-on Therapy to Metformin in Patients with Type 2 Diabetes

A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Evaluate the Efficacy and Safety of Daily Oral XXX 25 mg and 50 mg Compared to Placebo When Used in Combination with XXX in Subjects with Type 2 Diabetes

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of XXX in Patients with Type 2 Diabetes

A 26-week, multi-centre, multinational, open-label, 2-arm parallel, randomized, treat-to-target trial in insulin naïve subjects with T2DM inadequately controlled on a maximum tolerated dose or maximum dose according to local label of XXX in conjunction with XXX

A Phase III, 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of XXX in Insulin-Naïve Patients with Type 2 Diabetes Mellitus not Adequately Controlled with Oral Antihyperglycemic Drugs with a 6-month Comparative Extension Period

Irritable Bowel Syndrome

A Phase III, Open-Label, Long-Term Safety and Tolerability Study of XXX in Patients with Irritable Bowel Syndrome with Constipation (IBS-C)

A Second Phase III, Randomized, 12-Week, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of XXX in Patients with Irritable Bowel Syndrome with Constipation (IBS-C)

SUB-INVESTIGATOR TRIAL EXPERIENCE (*continued*):

A Phase III Study to Assess Repeat Treatment Efficacy and Safety of XXX in Subjects with Irritable Bowel Syndrome with Diarrhea (IBS-D)

A 12-Week, Randomized, Double-Blind, Placebo-Controlled Study of XXX in Subjects with Diarrhea-Predominant Irritable Bowel Syndrome

A Phase III Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy, Safety, and Tolerability of XXX in the Treatment of Patients With Diarrhea-Predominant Irritable Bowel Syndrome

Pain

A Safety and Efficacy Evaluation of XXX Laxative in Adults Experiencing Non-Idiopathic Constipation

A Double-blind, Randomized, Placebo-controlled, 24-week, Phase III Study Recruiting Males Over the Age of 50 and Post-menopausal Females with Documented Knee OA and Moderate Knee Pain

A Randomized Withdrawal, Double-blind, Placebo-controlled Phase III Trial to Evaluate the Efficacy and Safety of XXX ® Tablet, XXX, in Patients with Moderate-to-Severe Chronic Low Back Pain

A Phase III, Multicenter Long Term Observational Study of Subjects from XXX Studies Who Undergo a Total Knee, Hip, or Shoulder Replacement

A Phase III, Randomized, Double Blind, Placebo and Active-Controlled, Multicenter, Parallel-Group Study of the Analgesic Efficacy and Safety of XXX in Adult Patients with Chronic Low Back Pain

A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Analgesic Efficacy and Safety of a Dose Titration Regimen for the Subcutaneous Administration of XXX in Patients with Osteoarthritis of the Hip or Knee

An Open-Label Extension (OLE), Long-term Safety and Tolerability Study of XXX in Patients with Chronic Idiopathic Constipation (CIC)

A Randomized, 12-Week, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of XXX in Patients with Chronic Idiopathic Constipation

A Randomized Double-blind, Placebo-controlled, Parallel-group, Multicenter, Phase III Study to Evaluate the Cardiovascular Safety of XXX for the Treatment of Opioid-induced Constipation in Subjects with Non-malignant Pain Receiving Opioid Therapy

SUB-INVESTIGATOR TRIAL EXPERIENCE (*continued*):

A Phase III, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of XXX in the Treatment of Opioid-induced Constipation in Subjects with Non-malignant Pain Receiving Opioid Therapy

A Phase III, 6-Month, Open-Label, Extension Study to Evaluate the Safety of XXX at 15 to 90 mg Every 12 Hours for Relief of Moderate to Severe Pain in Patients With Chronic Low Back Pain Who Require Opioid Treatment for an Extended Period of Time

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of XXX for the Treatment of Opioid-Induced Constipation in Adults Taking Opioid Therapy for Chronic Non-Cancer Pain

A Phase II Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study Using a Bayesian Adaptive Design to Assess the Efficacy, Safety, Tolerability, and Serum Exposure of Multiple Doses of XXX in Subjects with Painful Lumbar Radiculopathy

A Phase III, 12-Week, Randomized, Double-Blind, Placebo-Controlled, Randomized-Withdrawal Study to Evaluate the Efficacy and Safety of XXX at 30 to 90 mg Every 12 Hours for Relief of Moderate to Severe Pain in Opioid-Experienced Patients With Chronic Low Back Pain Who Require Opioid Treatment for an Extended Period of Time

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of XXX for the Treatment of Opioid-Induced Constipation in Adults taking Opioid Therapy for Chronic Non-Cancer Pain AND A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Long-Term Safety and Tolerability of XXX for the Treatment of Opioid-Induced Constipation in Adults taking Opioid Therapy for Chronic Non-Cancer Pain

A Phase III, Open Label Long Term Safety Study: An Open-Label Study to Assess the Long-Term Safety of XXX in Patients with Opioid-Induced Constipation (OIC)

Men's and Women's Health

A Phase III, Active-Controlled, Safety and Efficacy Trial of XXX in Hypogonadal Men

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of XX in Subjects with Moderate to Severe Endometriosis-Associated Pain

A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of XXX on Bone Mineral Density (BMD) and Overall Safety in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated with an Oral XXX

A Phase IIb Study to Evaluate the Safety and Efficacy of XXX in Pre-Menopausal Women with Heavy Menstrual Bleeding associated with Uterine Fibroids

SUB-INVESTIGATOR TRIAL EXPERIENCE (*continued*):

Other Indications

A Phase III, Randomised, Open-label, Comparative Safety and Efficacy Trial of Intravenous XXX and XXX in Subjects with Iron Deficiency Anaemia who are Intolerant or Unresponsive to Oral Iron Therapy or in whom the Haemoglobin Measurement in Investigators' Opinion were Sufficiently Low as to Require Rapid Repletion of Iron Stores to Minimize the Risk of Receiving a Blood Transfusion

A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of 12 weeks of Treatment with Two Different Doses of Oral XXX as Compared to Placebo, Followed by a 12 week Open-label Treatment Period in Patients with Moderate to Severe Active Crohn's Disease

A Phase IV 26-Week Randomized, Double-Blinded, Active Controlled Study Comparing the Safety of XXX Fixed Dose Combination Versus XXX Monotherapy in Adolescents and Adults With Persistent Asthma

A Phase II, Double-Blind, Placebo-Controlled, Randomized study to assess the Efficacy, Safety, and Tolerability of following Multiple Intravenous Doses in Hypercholesterolemic subjects on maximum dose of XXX or XXX

Schizophrenia and Schizoaffective Disorders

A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, Parallel-group Study to Assess the Safety and Efficacy of XXX as Add-on Treatment for Cognitive Impairment in Subjects with Schizophrenia on Stable Doses of Antipsychotic Medication

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension XXX for Subcutaneous Use as Maintenance Treatment in Adult Patients with Schizophrenia

A Phase IIb, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study, to Evaluate the Efficacy, Safety, and Tolerability of XXX as Adjunctive Treatment in Patients with Cognitive Impairment Associated with Schizophrenia Treated with Antipsychotics

A Phase III, Study to Assess the Long-Term Safety, Tolerability, and Durability of Treatment Effect of XXX in Subjects with Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder

A Phase IIa, Multi-center, Double-Blind, Randomized, Parallel Group, 4-Week Inpatient Treatment Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Two Fixed Doses of XXX Compared to Placebo, Using XXX as an Active Control, in the Treatment of Acute Exacerbation of Schizophrenia

SUB-INVESTIGATOR TRIAL EXPERIENCE (*continued*):

A Randomized, 6-week, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of XXX for the Treatment of Schizophrenia or Schizoaffective Disorder in Subjects SWITCHED From Other Antipsychotic Agents and A 24-Week, Flexible-Dose, Open-Label Extension Study of Subjects Switched to XXX for the Treatment of Schizophrenia or Schizoaffective Disorder

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase II Study of the Safety and Efficacy of XXX in the Treatment of Cognitive Deficits in Schizophrenia (CDS)

A Long-Term, Open-Label, Multicenter Study of XXX Compared to Atypical Antipsychotic Standard of Care in Patients with DSM-IV-TR Schizophrenia

A Phase II, Multicenter, Double-Blind, Placebo-Controlled Comparator Study of 2 Doses of XXX versus Placebo in Patients with DSM-IV-TR Schizophrenia

A 17-Week, Phase II, Multi-center, Randomized, Double-Blind Study of Treatment with XXX Combined with Standard of Care Compared to placebo Combined with Standard of Care in the Treatment of Patients with DSM-IV-TR Schizophrenia with Prominent Negative Symptoms

A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Cognitive Enhancing Effect of XXX in Stable Patients with Schizophrenia